hemay007

Hemay007 is an orally active small molecule inhibitor of tumor necrosis factor alpha (TNF-α), developed by Hemay Pharmaceutical and Tianjin Hemay Pharmaceutical Sci-Tech. It is being investigated primarily for the treatment of autoimmune inflammatory diseases, including rheumatoid arthritis and ulcerative colitis. The drug acts as a TNF-α inhibitor, aiming to reduce inflammation by blocking the activity of this pro-inflammatory cytokine. Clinical development has reached phase II for both rheumatoid arthritis and ulcerative colitis, though a phase II trial in ulcerative colitis was terminated due to recruitment challenges[1][2][3][4][5].